Correlation between serum levels of interleukin-4 and alexithymia scores in healthy female subjects: Preliminary findings

Psychoneuroendocrinology

Volumn 29, Issue 4, 2004, Pages 557-562

  Corcos, Maurice ^a   Guilbaud, Olivier ^a   Paterniti, Sabrina ^a   Curt, Florence ^a   Hjalmarsson, Linea ^a   Moussa, Marlène ^b   Chambry, Jean ^a   Loas, Gwenolé ^c   Chaouat, Gérard ^b   Jeammet, Philippe ^a  

^a INSTITUT MUTUALISTE MONTSOURIS   (France)

^b HÔPITAL ANTOINE BÉCLÈRE   (France)

^c AMIENS UNIVERSITY HOSPITAL   (France)

Author keywords

Alexithymia; Cytokines; Interleukin 4

Indexed keywords

INTERLEUKIN 1; INTERLEUKIN 2; INTERLEUKIN 4;

ADULT; AGE DISTRIBUTION; ALEXITHYMIA; ARTICLE; BODY MASS; CONTROLLED STUDY; CORRELATION ANALYSIS; DEPRESSION; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HEALTH STATUS; HUMAN; LINEAR REGRESSION ANALYSIS; MENTAL HEALTH; NORMAL HUMAN; PREDICTION; PRIORITY JOURNAL;

EID: 9144250176     PISSN: 03064530     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0306-4530(03)00080-5     Document Type: Article

References (13)

1. Agarwal S.K., Marshall G.D. Jr. Dexamethasone promotes type 2 cytokine production primarily through inhibition of type 1 cytokines. J. Interferon Cytokine Res. 21:2001;147-551.
2. Bagby R., Parker J.D.A., Taylor G.J. Twenty-item Toronto Alexithymia Scale I: item selection and cross-validation of the factor structure; Twenty-item Toronto Alexithymia Scale II: convergent, discriminant, and concurrent validity. J. Psychosom. Res. 38:1994;33-40.
3. Dewaraja R., Tanigawa T., Araki S., Nakata A., Kawamura N., Ago Y., Sasaki Y. Decreased cytotoxic lymphocyte counts in alexithymia. Psychother. Psychosom. 66:1997;83-86.
4. Iwakabe K., Shimada M., Ohta A., Yahata T., Ohmi Y., Habu S., Nishimura T. The restraint stress drives a shift in Th1/Th2 balance toward Th2-dominant immunity mice. Immunol. Lett. 62:1998;39-43.
5. Lindholm T., Lehtinen V., Hyyppa M.T., Puukka P. Alexithymic features in relation to the dexamethasone suppression test in a Finnish population sample. Am. J. Psychiatry. 147:1990;1216-1219.
6. Loas G., Fremaux D., Marchand M.P. Etude de la structure factorielle et de la cohérence interne de la version française de l'échelle d'alexithymie de Toronto, 20 items (TAS-20) chez un groupe de 183 sujets sains. Encéphale. 21:1995;117-122.
7. Martin J.B., Pihl R.O. Influence of alexithymic characteristics on physiological and subjective stress responses in normal individuals. Psychother. Psychosom. 45:1986;66-67.
8. Rabavilas A.D. Electrodermal activity in low and high alexithymia neurotic patients. Psychother. Psychosom. 47:1987;101-104.
9. Shea J.D., Burton R., Girgis A. Negative affect, absorption, and immunity. Physiol. Behav. 53:1993;449-457.
10. Sheehan D.V., Lecrubier Y., Sheehan K.H., Amorim P., Janavs J., Weiller E., Hergueta T., Baker R., Dunbar G.C. The Mini-International Neuropsychiatric Interview (MINI): the development and validation of a structured diagnostic psychiatric interview for DSM-IV and ICD-10. J. Clin. Psychiatry. 59:(20 (Supplement)):1998;22-33.
11. Sifneos P.E. The prevalence of 'alexithymic' characteristics in psychosomatic patients. Psychother. Psychosom. 22:1973;255-262.
12. Todarello O., Casamassima A., Marinaccio M., La Pesa M.W., Caradonna L., Valentino L., Marinaccio L. Alexithymia, immunity and cervical intraepithelial neoplasia: a pilot study. Psychother. Psychosom. 61:1994;199-204.
13. Todarello O., Casamassima A., Daniele S., Marinaccio M., Fanciullo F., Valentino L., Tedesco N., Wiesel S., Simone G., Marinaccio L. Alexithymia, immunity and cervical intraepithelial neoplasia: replication. Psychother. Psychosom. 66:1997;208-213.